INTELLIGENT ONCOLOGY
choose a different vision
We provide a safe and more effective solution for patients in need of platin-treatment
Drug Response Predictor
Discover the future of cancer treatment with DRP® — the first-ever biomarker for cisplatin.
Our patented DRP® analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most—at the tumor site—providing safer and more effective cancer care.
iCIP™
The powerful combination of LiPlaCis® and DRP®.
LiPlaCis® delivers cisplatin directly to tumors, improving effectiveness and reducing toxicity, while DRP® identifies the patients most likely to benefit. This innovative approach ensures personalized, more effective cancer treatment with fewer side effects.
CHOSA is listed on Spotlight in Sweden. Use our interactive stock ticker to show the relevant market-information.
Key Opinion Leader Support
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our DRP® and advances our mission toward precision oncology.